Skip to main content

Advertisement

Fig. 3 | EJNMMI Research

Fig. 3

From: Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

Fig. 3

A 45-year-old women with metastatic lymphoepithelioma-like lung carcinoma treated with a second line of nivolumab. SCAN-1 showed left lung carcinoma with liver metastases (a maximum intensity projection image, MIP, arrows). SCAN-2 at 8 weeks of treatment (4 cycles) showed UPMD: increase in size of the primary lesion and appearance of numerous liver lesions (b MIP). SCAN-3 after two more cycles of nivolumab showed the disappearance of most liver lesions and a persistent large lung mass (c MIP). See Additional file 1: Figure S1 for axial views. Pseudo-progression was retrospectively diagnosed, and the classification was PMR according to iPERCIST. Nivolumab treatment was maintained for 7.1 months, and survival was 13.8 months

Back to article page